Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Lung Cancer Liquid Biopsy Market?

Recently, the lung cancer liquid biopsy market has experienced significant expansion. The market size is set to increase from $0.95 billion in 2024 to $1.12 billion in 2025, with a compound annual growth rate (CAGR) of 17.0%. The expansion seen in the historic period can be linked to a rising number of smokers and pollution-induced lung conditions, the escalating utilization of liquid biopsy in monitoring treatments, increased investment in oncology research, a growing demand for speedy and cost-efficient diagnostics, along with an increase in clinical trials.

In the coming years, the lung cancer liquid biopsy market is projected to experience accelerated growth. With a compound annual growth rate (CAGR) of 16.8%, it’s anticipated to increase to $2.08 billion by 2029. The expansion during the forecast period is attributed to factors such as the rising incidences of lung cancer, an escalating demand for minimally invasive diagnostic methods, an increasing preference for personalized treatment, heightened awareness about early detection of cancer, and a growing elderly population at risk of developing cancer. Notable emerging trends within this period include improvements in circulating tumor DNA (ctDNA) analysis techniques, advancements in exosome-based liquid biopsy technology, innovative progresses in microfluidics for isolating circulating tumor cells, the incorporation of artificial intelligence and machine learning for biomarker understanding, and technological advances in multiplex biomarker analysis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Which Factor Is Shaping The Future Of The Lung Cancer Liquid Biopsy Market?

The rise in lung cancer cases is anticipated to boost the expansion of the lung cancer liquid biopsy market. Lung cancer, often triggered by smoking and environmental hazards, is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs. The escalation of lung cancer is primarily due to persistent tobacco use, as smoking exposes the lungs to carcinogens that instigate anomalous cell growth. Lung cancer liquid biopsy facilitates by identifying cancer-related genomic mutations and tumor DNA in a blood sample, thus permitting early detection, choice of treatment, and the monitoring of disease development or treatment response. For example, the American Cancer Society (cancer.org), a non-profit entity committed to eradicating cancer, reported that as of January 1, 2022, 654,620 individuals in the U.S had a record of lung cancer, with a significant number living with metastatic disease. Approximately 80% were 65 years or older, and 55% were diagnosed within the last five years due to poor survival rates. Thus, the surge in lung cancer incidents is fueling the rise of the lung cancer liquid biopsy market.

What Is The Segment-Wise Breakdown Of The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Sconsumables Kits And Reagents, Software And Services

2) By Technology: Multi Gene-Parallel Analysis (Ngs), Single Gene Analysis (Pcr Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centres, Other End Users

Subsegments:

1) By Instruments: Pcr Instruments, Microarray Instruments, Next-Generation Sequencing (Ngs) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Which Trends Are Redefining The Future Landscape Of The Lung Cancer Liquid Biopsy Industry?

Leading firms in the lung cancer liquid biopsy market are concentrating on innovating and advancing technology, such as blood-derived lung cancer screening tests. These innovations aim to boost capacities for early detection, enhance diagnostic accuracy, and allow non-invasive, real-time tracking of tumor growth and the efficacy of treatments. A blood-derived lung cancer screening test is a non-intrusive method that examines biomarkers in the blood to detect early-stage lung cancer. For example, in October 2023, the American biotech company DELFI Diagnostics Inc. introduced FirstLook Lung. This is a blood-based liquid biopsy test constructed to help with the initial detection of lung cancer. It uses fragmentomics to find early lung cancer with high sensitivity and a negative predictive value of 99.8%, making it a suitable and easy-to-access first option for those at risk. The goal of the test is to augments early detection rates, raise rates of screening, and efficiently allocate imaging resources to those who need them most.

Which Companies Hold The Largest Market Share In The Lung Cancer Liquid Biopsy Sector?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

How Does Regional Performance Compare Across The Lung Cancer Liquid Biopsy Industry?

North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model